Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.

Stage unknownIselin, NJoutlooktherapeutics.comBiotechnology

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).

Facts
Year of incorporation
unknown
Revenue range (Form D)
Decline to Disclosesec.gov
Rounds on record
4
Disclosed raised
unknownsum of rounds with a disclosed amount only
Named investors
1
Financing history
4 rounds
  1. Apr 23, 2026
    Form D equity offering · $0 (form d sold) · 2 investors
    Fact SEC EDGAR Form D data sets (quarterly) · “Outlook Therapeutics, Inc. filed Form D: no sales yet of $5,000,000, Biotechnology”
  2. Jan 17, 2025
    Form D equity offering · $0 (form d sold) · 10 investors
    Fact SEC EDGAR Form D data sets (quarterly) · “Outlook Therapeutics, Inc. filed Form D: no sales yet of $31,977,359, Biotechnology”
  3. Apr 15, 2024
    Form D equity offering · $5.0M (form d sold) · 1 investors
    Fact SEC EDGAR Form D data sets (quarterly) · “Outlook Therapeutics, Inc. filed Form D: $5,000,002 sold of $13,250,005, Biotechnology”
  4. Mar 18, 2024
    Form D equity offering · $60.0M (form d sold) · 21 investors
    Fact SEC EDGAR Form D data sets (quarterly) · “Outlook Therapeutics, Inc. filed Form D: $60,000,000 sold of $159,000,000, Biotechnology”
Investors on record
1 edges
People
4 officers, 8 directors
Timeline
4
  1. May 7, 2026
    Outlook Therapeutics, Inc. filed Form D: no sales yet of $5,000,000, Biotechnology
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
  2. Jan 27, 2025
    Outlook Therapeutics, Inc. filed Form D: no sales yet of $31,977,359, Biotechnology
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
  3. Apr 16, 2024
    Outlook Therapeutics, Inc. filed Form D: $5,000,002 sold of $13,250,005, Biotechnology
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
  4. Mar 29, 2024
    Outlook Therapeutics, Inc. filed Form D: $60,000,000 sold of $159,000,000, Biotechnology
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
Evidence
61 observations
Every observation on this company